PROFILPELAJAR.COM

Relfovetmab

Relfovetmab
Monoclonal antibody
TypeWhole antibody
TargetNerve growth factor (NGF)
Clinical data
Trade namesPortela
Other namesZTS-00084768
Routes of
administration		Subcutaneous
ATCvet code
Legal status
Legal status
Identifiers
CAS Number
UNII
Chemical and physical data
FormulaC6580H10118N1760O2038S46
Molar mass147964.37 g·mol−1

Relfovetmab, sold under the brand name Portela, is a felinized monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats.[3] Relfovetmab targets nerve growth factor.[3] Nerve growth factor binds to TrkA receptors located on immune cells to elicit the release of additional proinflammatory mediators, including nerve growth factor itself.[2] These inflammatory mediators lead to further peripheral sensitization involved in pain perception.[2] The inhibition of nerve growth factor was demonstrated to provide relief from pain associated with osteoarthritis.[2]

Relfovetmab was authorized for veterinary use in the European Union in October 2025,[4] and in Canada in December 2025.[5]

Medical uses

Relfovetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[6]

Society and culture

In September 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Portela, solution for injection, intended for cats.[2] The applicant for this veterinary medicinal product is Zoetis Belgium.[2] Relfovetmab was authorized for veterinary use in the European Union in October 2025.[4]

Relfovetmab was authorized for veterinary use in Canada in December 2025.[5]

Names

Relfovetmab is the international nonproprietary name.[7]

Relfovetmab is sold under the brand name Portela.[4][5]

References

  1. ^ "Product information". Health Canada. 4 December 2025. Retrieved 22 December 2025.
  2. ^ a b c d e f "Portela EPAR". European Medicines Agency (EMA). 12 September 2025. Retrieved 28 September 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b c "Portela 2.5 mg". European Medicines Agency (EMA). 26 October 2025. Retrieved 22 December 2025.
  4. ^ a b c "Zoetis Receives European Commission Marketing Authorization for Portela (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats" (Press release). Zoetis. 29 October 2025. Retrieved 22 December 2025 – via Business Wire.
  5. ^ a b c "Zoetis Receives Health Canada Approval for Portela (relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats" (Press release). Zoetis. 5 December 2025. Retrieved 22 December 2025 – via Business Wire.
  6. ^ "Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 9-10 September 2025". European Medicines Agency (EMA). 12 September 2025. Retrieved 22 December 2025.
  7. ^ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). 2019. hdl:10665/330879.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.